清肝利胆退黄汤治疗婴儿胆汁淤积性肝病临床研究
|
摘要
目的:观察清肝利胆退黄汤治疗婴儿胆汁淤积性肝病的临床疗效,探讨和研究治疗过程中中药治疗的价值和意义,为研发新的治疗胆汁淤积性肝病的中成药提供临床依据。方法:选取婴儿胆汁淤积性肝病患儿100例,依据随机数字表按照双盲随机对照原则分为观察组和对照组,分别给予不同的治疗方法,分析疗效、各实验指标及临床症状及体征评分值的改善情况。结果:观察组胆红素下降水平较对照组有明显改善(P<0.05),但ALT及GGT两组差异不大(P>0.05)。观察组总有效率90.0%,明显优于对照组66.0%(P<0.05)。观察组患儿临床症状及体征评分改善情况优于对照组(P<0.05)。结论:清肝利胆退黄汤治疗婴儿胆汁淤积性肝病的疗效可靠,且未见不良反应情况。
Objective:To explore and study the value and significance of traditional Chinese medicine in the treatment of infantile cholestatic liver disease by observing the clinical efficacy of Qinggan Lidan Tuihuang decoction in the treatment of infantile cholestatic liver disease,and to provide a clinical basis for the development of new Chinese patent medicine for the treatment of cholestatic liver disease.Methods:We enrolled 100 infants with cholestatic liver disease.Based on the random number table,these infants were divided into observation group and the control group according to the double-blind randomized control principle.Then treated with different regimens.After the end of treatment,the curative effect,the improvement of various experimental indicators,clinical symptoms and physical signs scores were analyzed.Results:The level of bilirubin in the observation group was significantly improved compared with the control group(P<0.05),but the difference between the ALT and GGT groups was not significant(P>0.05).The total effective rate of the observation group was 90.0%,which was significantly better than that of the control group(66.0%)(P<0.05).The improvement of clinical symptoms and signs score in the observation group was better than that in the control group(P<0.05).Conclusion:Qinggan Lidan Tuihuang Decoction is effective in treating infantile cholestasis liver disease,and there are no adverse reactions.
Objective:To explore and study the value and significance of traditional Chinese medicine in the treatment of infantile cholestatic liver disease by observing the clinical efficacy of Qinggan Lidan Tuihuang decoction in the treatment of infantile cholestatic liver disease,and to provide a clinical basis for the development of new Chinese patent medicine for the treatment of cholestatic liver disease.Methods:We enrolled 100 infants with cholestatic liver disease.Based on the random number table,these infants were divided into observation group and the control group according to the double-blind randomized control principle.Then treated with different regimens.After the end of treatment,the curative effect,the improvement of various experimental indicators,clinical symptoms and physical signs scores were analyzed.Results:The level of bilirubin in the observation group was significantly improved compared with the control group(P<0.05),but the difference between the ALT and GGT groups was not significant(P>0.05).The total effective rate of the observation group was 90.0%,which was significantly better than that of the control group(66.0%)(P<0.05).The improvement of clinical symptoms and signs score in the observation group was better than that in the control group(P<0.05).Conclusion:Qinggan Lidan Tuihuang Decoction is effective in treating infantile cholestasis liver disease,and there are no adverse reactions.
引文
[1] 董永绥.婴儿胆汁淤积性肝病研究进展及展望[J].中国实用儿科杂志,2013,28(4):241-245.
[2] 周厚琴,张璐.中医药治疗淤胆性肝炎的研究进展[J].中国医院用药评价与分析,2018,18(12):1588-1590.
[3] 胆汁淤积性肝病诊断治疗专家委员会.胆汁淤积性肝病诊断治疗专家共识[J].中华实验和临床感染病杂志,2009,3(4):57-64.
[4] 潘定举.中医主证程度的量化赋分值与症候疗效评价的相关性分析[J].中药新药与临床杂志,2009,28(10):797-800.
[5] 鄢素琪,邓玉萍.利胆合剂治疗婴儿巨细胞病毒感染胆汁淤积性肝病120例临床观察[J].中国中西医结合杂志,2012,32(12):1632-1637.
[6] 钱飞,羊二尚.熊去氧胆酸联合黄疸茵陈颗粒治疗婴儿胆汁淤积性黄疸疗效观察[J].陕西医学杂志,2013,42(8):1076-1077.
[7] Rima F,Ulrich B,Udeme E,et al.Guideline for the evaluation of cholestatic jaundice in infants:joint recommendations of the north American society for pediatric gastroenterology,hepatology,and nutrition(NASpGHAN) and the european society for pediatric gastroenterology,hepatology,and nutrition(ESpGHAN)[J].Journal Pediatr Gastroenterol Nutr,2017,64(1):154-168.
[8] 朱启瑢,王建设.婴儿胆汁淤积症的鉴别诊断思路[J].临床肝胆病杂志,2011,27(7):679-693.
[9] 李在玲.婴儿胆汁淤积性肝病的治疗[J].实用儿科临床杂志,2012,27(7):476-478.
[10] 魏建华,刘学敏.茵陈蒿的现代药理研究[J].中西医结合与祖国医学,2009,13(8):734-735.
[11] 蒙爱东.药用植物广金钱草的研究进展[J].广西科学院学报,2008,24(2):148-151.
[12] 何贵坤,黄小桃.广金钱草对肝内胆汁淤积大鼠的干预作用[J].中药新药与临床药理,2015,26(2):152-156.
[13] 洪照友,高毅,詹兴海.中药虎杖对大鼠肝脏缺血性损伤保护的形态学观察[J].世界华人消化杂志,2000,8(2):162-164.
[14] 张超.栀子柏皮汤方药3种方法≤1000Da提取液保肝退黄作用比较[J].山东中医药大学学报,2014,38(3):270-272.
[15] 刘成,杨宗国.茯苓多糖退黄作用的实验研究[J].中国实验方剂学杂志,2012,18(10):195-198.
[16] Hur JM,Choi JW,Park JC.Effects of methanol extract of Alisma orientale rhizome and its major component,alisol B 23-acetate,on hepatic drug metabolizing enzymes in rats treated with bromobenzene[J].Archives of Pharmacal Research,2007,30(12):1543-1549.
[2] 周厚琴,张璐.中医药治疗淤胆性肝炎的研究进展[J].中国医院用药评价与分析,2018,18(12):1588-1590.
[3] 胆汁淤积性肝病诊断治疗专家委员会.胆汁淤积性肝病诊断治疗专家共识[J].中华实验和临床感染病杂志,2009,3(4):57-64.
[4] 潘定举.中医主证程度的量化赋分值与症候疗效评价的相关性分析[J].中药新药与临床杂志,2009,28(10):797-800.
[5] 鄢素琪,邓玉萍.利胆合剂治疗婴儿巨细胞病毒感染胆汁淤积性肝病120例临床观察[J].中国中西医结合杂志,2012,32(12):1632-1637.
[6] 钱飞,羊二尚.熊去氧胆酸联合黄疸茵陈颗粒治疗婴儿胆汁淤积性黄疸疗效观察[J].陕西医学杂志,2013,42(8):1076-1077.
[7] Rima F,Ulrich B,Udeme E,et al.Guideline for the evaluation of cholestatic jaundice in infants:joint recommendations of the north American society for pediatric gastroenterology,hepatology,and nutrition(NASpGHAN) and the european society for pediatric gastroenterology,hepatology,and nutrition(ESpGHAN)[J].Journal Pediatr Gastroenterol Nutr,2017,64(1):154-168.
[8] 朱启瑢,王建设.婴儿胆汁淤积症的鉴别诊断思路[J].临床肝胆病杂志,2011,27(7):679-693.
[9] 李在玲.婴儿胆汁淤积性肝病的治疗[J].实用儿科临床杂志,2012,27(7):476-478.
[10] 魏建华,刘学敏.茵陈蒿的现代药理研究[J].中西医结合与祖国医学,2009,13(8):734-735.
[11] 蒙爱东.药用植物广金钱草的研究进展[J].广西科学院学报,2008,24(2):148-151.
[12] 何贵坤,黄小桃.广金钱草对肝内胆汁淤积大鼠的干预作用[J].中药新药与临床药理,2015,26(2):152-156.
[13] 洪照友,高毅,詹兴海.中药虎杖对大鼠肝脏缺血性损伤保护的形态学观察[J].世界华人消化杂志,2000,8(2):162-164.
[14] 张超.栀子柏皮汤方药3种方法≤1000Da提取液保肝退黄作用比较[J].山东中医药大学学报,2014,38(3):270-272.
[15] 刘成,杨宗国.茯苓多糖退黄作用的实验研究[J].中国实验方剂学杂志,2012,18(10):195-198.
[16] Hur JM,Choi JW,Park JC.Effects of methanol extract of Alisma orientale rhizome and its major component,alisol B 23-acetate,on hepatic drug metabolizing enzymes in rats treated with bromobenzene[J].Archives of Pharmacal Research,2007,30(12):1543-1549.